1. EachPod

ReachMD CME - Podcast

ReachMD CME

 ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Health Medicine Science & Medicine
Update frequency
every day
Episodes
499
Years Active
2019 - 2025
Share to:
Emerging Treatment Approaches for EBC

Emerging Treatment Approaches for EBC

CME credits: 1.50
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-treatment-approaches-for-ebc/29830/

Treatment decision-making in breast cancer is…

Mon 30 Dec 2024
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?

The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?

Mon 30 Dec 2024
Management of HER2-Low MBC Following First-Line Disease Progression

Management of HER2-Low MBC Following First-Line Disease Progression

CME credits: 1.50
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/management-of-her2-low-mbc-following-first-line-disease-progression/29834/

Treatment decis…

Mon 30 Dec 2024
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence

Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence

Mon 30 Dec 2024
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

CME credits: 1.25
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-msi-hdmmr-mcrc-the-role-of-immunotherapy/29850/

The NCCN Clinical …

Mon 30 Dec 2024
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC

Mon 30 Dec 2024
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

Emerging Directions in Biomarker-Directed Therapy for GI Malignancies

CME credits: 1.25
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-biomarker-directed-therapy-for-gi-malignancies/29853/

The NCCN Clin…

Mon 30 Dec 2024
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice

Mon 30 Dec 2024
The Evolving Treatment Landscape for MBC: Emerging Therapies

The Evolving Treatment Landscape for MBC: Emerging Therapies

CME credits: 1.50
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-treatment-landscape-for-mbc-emerging-therapies/29831/

Treatment decision-maki…

Mon 30 Dec 2024
Management of HR+, HER2- High-Risk EBC

Management of HR+, HER2- High-Risk EBC

CME credits: 1.50
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/management-of-hr-her2-high-risk-ebc/29833/

Treatment decision-making in breast cancer is c…

Mon 30 Dec 2024
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion

Mon 30 Dec 2024
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence

Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence

Mon 30 Dec 2024
Unmasking IgAN: From Suspicion to Timely Diagnosis

Unmasking IgAN: From Suspicion to Timely Diagnosis

CME credits: 0.25
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/unmasking-igan-from-suspicion-to-timely-diagnosis/26629/

Because renal biopsy is required …

Mon 30 Dec 2024
Expert Viewpoint: Optimizing Breast Cancer Treatment

Expert Viewpoint: Optimizing Breast Cancer Treatment

CME credits: 1.50
Valid until: 30-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/expert-viewpoint-optimizing-breast-cancer-treatment/29832/

Treatment decision-making in br…

Mon 30 Dec 2024
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study

First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study

Mon 30 Dec 2024
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence

Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence

Mon 30 Dec 2024
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations

Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations

Mon 30 Dec 2024
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC

Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC

Mon 30 Dec 2024
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer

Mon 30 Dec 2024
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer

Mon 30 Dec 2024
Disclaimer: The podcast and artwork embedded on this page are the property of ReachMD. This content is not affiliated with or endorsed by eachpod.com.